Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction
A Prospective, Multicenter, Open-label, Single-arm Clinical Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) IOL for Correction of Aphakia Following Cataract Extraction
A study to learn how well an artificial lens, called an intraocular lens (IOL), works in adults who have cataract surgery. During this type of surgery, the eye's natural lens is removed and replaced with an artificial lens to help restore vision.
The main goal of the study is to evaluate vision after the lens is placed in the eye. About one year after surgery, participants' vision will be measured to understand how clearly they can see.
The study will also look at how the lens performs over time, including how well it remains in place in the eye.
The results of this study will help provide more information about how this lens performs in adults undergoing cataract surgery.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Director, Clinical Operations
- Telefonní číslo: 919-433-1600
- E-mail: Clinical@KowaUS.com
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Are able and willing to provide written informed consent, attend all scheduled visits, and comply with all trial procedures and follow-up
- Have a study eye with visually significant cataract for which phacoemulsification cataract extraction and posterior chamber IOL implantation is indicated
- Meet all other inclusion criteria outlined in the clinical study protocol
Exclusion Criteria:
- Have serious systemic disease that could increase operative risk or conditions that can confound the surgical outcome
- Within 30 days of the Screening Visit, use of systemic medications with significant ocular side effects or any medications that could confound the outcome or increase participant risk
- Meet any other exclusion criteria outlined in the clinical study protocol
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: KI-362-US1
Participants in this study receive an artificial lens (intraocular lens) implanted in the eye to replace the eye's natural lens that has been removed due to cataract surgery.
The lens is delivered using a single-use, preloaded device that helps the surgeon place the lens safely and precisely into the natural lens capsule of the eye.
|
Injector and one-piece (1P) monofocal IOL
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Proportion of Participants whose BCDVA Achieved 0.30 logMAR or Better at Form 5
Časové okno: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
A binary outcome of achieving best-corrected distance visual acuity (BCDVA) of 0.30 logarithm of the minimum angle of resolution (logMAR) or better, or not, at postoperative days 330-390 (Form 5) BCDVA will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) illuminated charts |
Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
|
Proportion of Participants with Incidence of Selected Ocular Adverse Events
Časové okno: Baseline through end of study (up to 15 months)
|
This safety outcome measure evaluates whether participants experience any of the following ocular adverse events after treatment, recorded as a binary outcome (occurrence: yes/no). Cumulative adverse events assessed include Cystoid macular edema, Hypopyon, Endophthalmitis, lens dislocation from the posterior chamber, Pupillary block, Retinal detachment, and secondary surgical interventions (excluding posterior capsulotomies). In addition, persistent adverse events are assessed as present or absent, including corneal stroma edema, persistent Cystoid macular edema, Iritis, and elevated intraocular pressure requiring treatment. |
Baseline through end of study (up to 15 months)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Proportion of Participants with Lens Axis Misalignment of <10 degrees From Baseline to Form 4
Časové okno: Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
|
Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time.
Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit (Form 4) remains within predefined thresholds.
|
Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
|
|
Proportion of Participants with Lens Axis Misalignment of <10 degrees From Baseline to Form 5
Časové okno: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time.
Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit (Form 5) remains within predefined thresholds.
|
Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
|
Proportion of Participants with Lens Axis Misalignment of <20 degrees From Baseline to Form 4
Časové okno: Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
|
Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time.
Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit 4 (Form 4) remains within predefined thresholds.
|
Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
|
|
Proportion of Participants with Lens Axis Misalignment of <20 degrees From Baseline to Form 5
Časové okno: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time.
Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit (Form 5) remains within predefined thresholds.
|
Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Studijní židle: Shona Pendse, MD, MMSc, Kowa Research Institute, Inc.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- KI-362-US1-301
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .